Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape

DelveInsight's 2026 report reveals a robust AMD clinical trial pipeline with 90+ active players developing 100+ pipeline drugs across various clinical stages. The report highlights promising therapies including elamipretide, 4D-150, MK-8748, and SAR402663, with approximately 15+ drugs in late-stage development. Recent advances include Merck's Phase IIb/III trial initiation for MK-8748, 4D Molecular Therapeutics' Phase III enrollment completion for 4D-150, and FDA fast-track designation for SAR402663.

06/18/2026, 1:00 PM • GlobeNewswire

REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX

REGENXBIO Inc. (NASDAQ: RGNX) faces a class action lawsuit for securities violations. The company allegedly made false and misleading statements about the safety and efficacy of its RGX-111 product candidate while concealing adverse information from investors. The FDA placed a clinical hold on RGX-111 after a clinical trial participant developed a tumor. Shareholders who purchased shares between February 9, 2022 and January 27, 2026 are encouraged to contact DJS Law Group regarding potential recovery.

04/14/2026, 8:05 PM • Benzinga

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX

Pomerantz Law Firm has filed class action lawsuits against REGENXBIO Inc., AMC Entertainment Holdings, Inc., and Upstart Holdings, Inc. for alleged securities fraud and unlawful business practices. The REGENXBIO lawsuit was triggered by an FDA clinical hold on its gene therapy candidates RGX-111 and RGX-121, which caused the stock to fall 17.9% on January 28, 2026. Investors with losses are urged to contact the firm by the April 14, 2026 deadline to potentially serve as lead plaintiff.

04/14/2026, 3:51 PM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in AMC Entertainment Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMC; APE

Pomerantz Law Firm has filed class action lawsuits against AMC Entertainment Holdings, REGENXBIO Inc., and Upstart Holdings, alleging securities fraud and unlawful business practices. The AMC lawsuit specifically concerns APE preferred equity unit holders who were excluded from a special dividend following conversion to common stock due to an undisclosed loophole in the Certificate of Designations. Investors have until April 20, 2026, to request Lead Plaintiff status.

04/14/2026, 3:46 PM • GlobeNewswire

Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors

REGENXBIO investors can file a class action lawsuit for securities purchased between February 9, 2022 and January 27, 2026. The lawsuit alleges the company made false statements about the safety and efficacy of its RGX-111 gene therapy. On January 28, 2026, REGENXBIO announced the FDA placed a clinical hold on RGX-111 after an intraventricular CNS tumor was found in a trial participant, causing the stock to fall nearly 18%.

04/14/2026, 9:00 AM • GlobeNewswire

REGENXBIO DEADLINE: ROSEN, A LEADING AND RANKED FIRM, Encourages REGENXBIO, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action - RGNX

Rosen Law Firm is reminding REGENXBIO investors who purchased securities between February 9, 2022 and January 27, 2026 of the April 14, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that REGENXBIO made false and misleading statements about the efficacy and safety of its RGX-111 gene therapy trial while providing overwhelmingly positive public assertions, resulting in investor damages.

04/12/2026, 11:14 AM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against REGENXBIO Inc. alleging that the company made materially false and misleading statements regarding its RGX-111 gene therapy development and clinical trial results. The lawsuit covers investors who purchased securities between February 9, 2022 and January 27, 2026, with a lead plaintiff deadline of April 14, 2026.

04/06/2026, 12:00 PM • GlobeNewswire

RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is seeking lead plaintiffs for a securities fraud class action lawsuit against REGENXBIO Inc. The lawsuit alleges the company made false and misleading statements about its product candidate RGX-111, concealing negative efficacy and safety data while presenting overwhelmingly positive statements to investors. The fraud was allegedly revealed when an intraventricular CNS tumor was discovered in a study participant. Investors who purchased securities between February 9, 2022 and January 27, 2026 are encouraged to join the case.

04/06/2026, 4:04 AM • Benzinga

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

A securities class action lawsuit has been filed against REGENXBIO, Inc. for allegedly providing materially false and misleading statements regarding the efficacy and safety of its RGX-111 gene therapy trial while making positive assertions to investors. The firm is seeking a lead plaintiff by April 14, 2026, for investors who purchased securities between February 9, 2022 and January 27, 2026.

04/05/2026, 7:52 PM • GlobeNewswire

TCPC IMPORTANT DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages BlackRock TCP Capital Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action – TCPC

Rosen Law Firm is notifying investors in BlackRock TCP Capital Corp. (TCPC) and other companies about ongoing securities class action lawsuits. The firm is seeking a lead plaintiff by the April 6, 2026 deadline. According to the lawsuit, BlackRock TCP made materially false statements regarding investment valuations, portfolio quality, and net asset value, resulting in investor losses.

04/05/2026, 7:29 PM • GlobeNewswire

ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

A securities class action lawsuit has been filed against REGENXBIO, Inc. for allegedly providing investors with false and misleading statements regarding its RGX-111 gene therapy candidate. The firm claims defendants made overwhelmingly positive assertions about the drug's trial success while concealing material adverse facts about efficacy and safety. Investors who purchased REGENXBIO securities between February 9, 2022 and January 27, 2026 may be eligible for compensation. The lead plaintiff deadline is April 14, 2026.

04/04/2026, 9:12 PM • GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm

Law firm Bragar Eagel & Squire announces class action lawsuits against PayPal Holdings and REGENXBIO Inc. PayPal faces allegations of providing false revenue projections and unachievable 2027 targets, leading to a 20% stock decline after disappointing Q4 2025 results. REGENXBIO is sued over concealed safety concerns regarding its RGX-111 gene therapy, which experienced a 17.8% stock drop following an FDA clinical hold due to a tumor found in a trial participant.

04/03/2026, 2:03 PM • GlobeNewswire

ROSEN, HIGHLY RANKED INVESTOR RIGHTS COUNSEL, Encourages Snowflake Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SNOW

Rosen Law Firm is soliciting investors who purchased securities of Snowflake Inc., REGENXBIO Inc., and Plug Power Inc. during specified class periods to join ongoing securities class action lawsuits. The lawsuits allege that these companies made misleading positive statements about their businesses while failing to disclose material negative information that subsequently impacted stock prices.

04/01/2026, 5:56 PM • GlobeNewswire

RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is seeking investors to join a class action lawsuit against REGENXBIO Inc. for securities fraud. The company allegedly made false and misleading statements about its product candidate RGX-111, concealing negative efficacy and safety data while presenting overwhelmingly positive statements. The fraud was revealed when an intraventricular CNS tumor was discovered in a study participant, causing investor losses.

03/30/2026, 11:00 AM • GlobeNewswire

REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX

REGENXBIO Inc. (NASDAQ: RGNX) faces a class action lawsuit for securities violations. The company allegedly made false and misleading statements about the safety and efficacy of its RGX-111 product candidate while concealing adverse information from investors. The FDA placed a clinical hold on RGX-111 after a clinical trial participant developed a tumor. Shareholders who purchased shares between February 9, 2022 and January 27, 2026 are encouraged to contact DJS Law Group, with an April 14, 2026 deadline for participation.

03/30/2026, 4:06 AM • Benzinga